Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in transactions on October 9, 2025.
• Khattar exercised employee stock options to acquire 81,250 shares of common stock at an exercise price of $25.3 per share.
• Following the option exercise, Khattar sold 58,371 shares of common stock at a weighted average price of $50.55 per share, with prices ranging from $50.11 to $51.09.
• An additional 1,529 shares of common stock were sold at a weighted average price of $51.46 per share, with prices ranging from $51.14 to $51.76.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
• After these transactions, Khattar directly beneficially owns 1,206,578 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While insider selling can sometimes be viewed negatively, the transactions were pre-planned under a 10b5-1 plan, mitigating concerns about reactive selling. The exercise of options at a significantly lower price indicates a profitable event for the executive.

Positives

• The exercise of employee stock options at $25.3 per share, significantly below the market sale prices, indicates a profitable transaction for the insider.
• The transactions were conducted under a Rule 10b5-1 trading plan, suggesting the sales were pre-scheduled and not based on immediate, non-public information.

Negatives

• The sale of common stock by a key executive, even if pre-planned, can sometimes be interpreted by the market as a reduction in insider confidence.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the pharmaceutical sector.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, though the pre-planned nature under a 10b5-1 plan suggests it is not based on new, adverse information. The overall impact on shareholder sentiment is likely neutral to slightly negative.

Key Dates

Recommendation

The filing details an insider's exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. While the exercise of options is a positive for the insider, the sale of shares, even if planned, does not provide a strong catalyst for a 'buy' recommendation. Conversely, it's not a 'sell' signal given the pre-planned nature and the executive's continued significant ownership. Therefore, a 'hold' recommendation is appropriate as this transaction alone does not fundamentally alter the investment thesis for Supernus Pharmaceuticals.

Keywords

Supernus Pharmaceuticals, SUPN, Jack Khattar, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Beneficial Ownership, Pharmaceuticals